What Is Nuclear Oncology?
Nuclear oncology is a subspecialty within nuclear medicine that focuses specifically on the use of radioactive materials in cancer care. It spans the entire journey from detecting cancer to treating it. What makes nuclear oncology distinct from other branches of oncology or radiology is its dual capability: the same molecular targets used to find cancer can often be used to deliver targeted radiation treatment directly to tumor cells.
This concept, called theranostics (a combination of “therapeutics” and “diagnostics”), has become one of the most significant advances in cancer care in recent years. Instead of treating cancer with a one-size-fits-all approach, nuclear oncology personalizes both diagnosis and treatment at the molecular level.
The Diagnostic Side: Molecular Imaging
The diagnostic arm of nuclear oncology relies on molecular imaging techniques, primarily PET CT and SPECT. These scans use radioactive tracers that are designed to bind to specific molecules on cancer cells or in the tumor environment.
Unlike conventional imaging (CT, MRI, ultrasound) that shows what a tumor looks like structurally, molecular imaging reveals what a tumor is doing biologically. It answers questions like: Is this mass metabolically active? Does it express a specific receptor? Is the cancer responding to treatment, or is it progressing?
Over the past decade, the number of available PET tracers has grown substantially. FDG remains the most widely used tracer for general oncology, but disease-specific tracers like PSMA (prostate cancer), DOTANOC (neuroendocrine tumors), FAPI (tumor stroma), and many others now provide highly targeted imaging for specific cancer types. Each tracer acts like a molecular probe, seeking out its target wherever it may be in the body.
This molecular information is critical for staging (determining how far cancer has spread), treatment planning, response assessment, and detecting recurrence. In many cancers, nuclear medicine imaging has become an essential part of the diagnostic workup.
The Therapeutic Side: Targeted Radionuclide Therapy
The therapeutic arm of nuclear oncology uses the same molecular targeting principle, but instead of a low-energy tracer for imaging, a therapeutic radioactive isotope is attached to the targeting molecule. When this compound is administered, it seeks out cancer cells, binds to them, and delivers targeted radiation directly to the tumor while largely sparing surrounding healthy tissue.
This approach is called radioligand theranostics, and it represents a fundamentally different way of delivering radiation compared to external beam radiotherapy. Rather than directing a radiation beam from outside the body, the radiation source travels through the bloodstream and delivers treatment from within.
Established Therapies
Several radioligand therapies are now well-established in clinical practice:
Radioiodine therapy for thyroid cancer is one of the oldest and most successful applications. Thyroid cancer cells absorb iodine, so radioactive iodine (I-131) selectively destroys thyroid cancer cells after surgery. This has been used for decades with excellent outcomes.
Lutetium-177 DOTATATE for neuroendocrine tumors targets somatostatin receptors on NET cells. The NETTER-1 trial demonstrated significant improvements in progression-free survival, and this therapy is now approved and available at specialized centers.
Lutetium-177 PSMA therapy for prostate cancer targets PSMA on prostate cancer cells. The VISION trial showed improved overall survival in men with metastatic castration-resistant prostate cancer who had progressed after other treatments. This approval has been a landmark moment for nuclear oncology.
The Theranostic Principle
The theranostic approach follows a logical sequence. First, a diagnostic PET scan is performed using a tracer that targets a specific molecule on cancer cells. If the scan shows strong uptake (meaning the cancer cells express the target in abundance), the patient is likely to respond to therapy using the same targeting molecule paired with a therapeutic isotope. If the scan shows poor uptake, the patient may not benefit and can be spared an ineffective treatment.
This is personalized medicine in action. The diagnostic scan serves as a companion biomarker that predicts who will benefit from the therapy. It reduces the trial-and-error approach that can occur with other cancer treatments.
The Role of the Nuclear Medicine Physician
A nuclear medicine physician specializing in oncology sits at the intersection of imaging and therapy. Their responsibilities include:
Interpreting diagnostic scans: Reading PET CT and SPECT studies requires understanding tumor biology, normal tracer distribution, and the clinical context of each patient.
Treatment planning: For radioligand therapies, the nuclear medicine physician assesses scan findings to determine whether a patient is a suitable candidate, plans the treatment dose, and monitors for side effects.
Dosimetry: Calculating the radiation dose delivered to tumors and normal organs is an increasingly important part of treatment optimization. Personalized dosimetry aims to give each patient the dose most likely to control their cancer while minimizing side effects.
Multidisciplinary collaboration: Nuclear oncologists work closely with medical oncologists, radiation oncologists, surgeons, radiologists, and other specialists in tumor boards. Their molecular imaging expertise provides unique insights that influence treatment decisions across the team.
Future Directions
Nuclear oncology is evolving rapidly. Several areas of development are worth noting:
Newer tracers and targets: Research is continuously identifying new molecular targets and developing corresponding tracers. Targets like FAPI, GPC3, CAIX, CXCR4, and others are expanding the range of cancers that can be imaged and potentially treated with radioligands.
Combination therapies: Studies are exploring whether radioligand therapy combined with other treatments (immunotherapy, chemotherapy, external radiation) can improve outcomes beyond what each therapy achieves alone. Early results in several cancer types are promising.
Alpha-particle therapy: Most current radioligand therapies use beta-emitting isotopes like Lutetium-177. Alpha-emitting isotopes (like Actinium-225) deliver more potent radiation over shorter distances, potentially offering greater cancer cell killing with less collateral damage. Research in alpha therapy is accelerating.
Artificial intelligence: AI and machine learning are being integrated into image interpretation and dosimetry calculations, potentially improving accuracy and efficiency.
Expanded indications: As clinical trials demonstrate the effectiveness of radioligand therapies in more cancer types and earlier lines of treatment, access to these therapies is expected to broaden.
What This Means for Patients
Nuclear oncology offers something that few other specialties can: the ability to see a cancer at the molecular level and then treat it through the same molecular pathway. For patients whose cancers express specific targets, this can mean a treatment option that is both precise and less toxic than traditional chemotherapy.
If you are undergoing cancer treatment, or if conventional therapies have not been effective, ask your oncologist whether nuclear medicine imaging or radioligand therapy could play a role in your care. A consultation with a nuclear medicine physician can help determine if your cancer expresses a target that can be used for both imaging and treatment. The field is advancing quickly, and options that did not exist even a few years ago may now be available for your situation.